Preferences help
enabled [disable] Abstract
Number of results
2009 | 58 | 1-2 | 187-198
Article title

Dwie twarze arsenu

Title variants
Two faces of arsenic
Languages of publication
Arsenic is a metalloid which occurs naturally in air, as well as in soil and water. Its sources are both natural and antropogenic. Form in which arsenic compounds occur, depends on oxygen levels and involvement in biological processes. For 2500 years arsenic has been used by man. In antiquity, compounds, like realgar or aurypigmentum, were used in treatment of many diseases. Arsenic trioxide, on the other hand, was used as a poison. In 1908 Paul Ehrlich won Nobel Price for introducing arsenic compounds into medicine, especially salwarsan for treatment of lues,. Also in present medicine a variety of diseases (i.e. acute promielocytic leukemia or sleeping sickness) is treated with arsenic compounds. Millions of people are suffering because of chronic exposure to arsenic. There is need for further investigation to better understand molecular mechanisms of arsenic toxicity and action of arsenic-containing medicines, as well as of its role in environment.
Physical description
  • Zakład Genetyki i Fizjologii Komórki, Instytut Genetyki i Mikrobiologii, Uniwersytet Wrocławski, Przybyszewskiego 63/77, 51-148 Wrocław, Polska
  • Zakład Genetyki i Fizjologii Komórki, Instytut Genetyki i Mikrobiologii, Uniwersytet Wrocławski, Przybyszewskiego 63/77, 51-148 Wrocław, Polska
  • Zakład Genetyki i Fizjologii Komórki, Instytut Genetyki i Mikrobiologii, Uniwersytet Wrocławski, Przybyszewskiego 63/77, 51-148 Wrocław, Polska
  • Alibu V. C., Richter C., Voncken F., Marti G., Shahi S., Renggli C., K., Seebeck T., Brun R., Clayton C., 2006. The role of Trypanosoma brucei MRPA in melarsoprol susceptibility. Mol. Biochem. Parasitol. 146, 38-44.
  • Antman K. H., 2001. Introduction: The history of arsenic trioxide in cancer therapy. Oncologist 6, 1-2.
  • Biedroń M., Wróbel T., Mazur G., Kuliczkowski K., 2003. Zastosowanie trójtlenku arsenu w leczeniu nowotworów hematologicznych. J. Oncol. 53, 422.427.
  • Bielański A., 1987. Podstawy chemii nieorganicznej. Tom 2. PWN WARSZAWA, 333-391.
  • Bouteille B., Oukem O., Bisser S., Dumas M., 2003. Treatment perspectives for human African trypanosomiasis. Fundam. Clin. Pharmacol. 17, 171-181.
  • Bun-Ya M., Shikata K., Nakade S., Yompakdee C., Harashima S., Oshima Y., 1996. Two new genes, PHO86 and PHO87, involved in inorganic phosphate uptake in Saccharomyces cerevisiae. Curr. Genet. 29, 344-351.
  • Bylińska E., Giża W., Żyrnicki W., 2005. Accumulation of arsenic and mercury in plants from a post-industrial area in the Zloty Stok Region. Ecol. Chem. Engineer. 12, 773-784.
  • Caussy D., 2003. Case studies of the impact of understanding bioavailability: arsenic. Ecotoxicol. Environ. Safety 56, 164-173.
  • Chou W. C., Chen H., Yu S. L., Cheng L., Yang P. C., Dang C. V., 2005. Arsenic suppresses gene expression in promyelocytic leikemia cells partly through Sp1 oxidation. Blood 106, 304-310.
  • Dembitsky V. M., Levitsky D. O., 2004. Arsenolipids. Prog. Lipid Res. 43, 403-448.
  • Dilda P. J., Hogg P. J., 2007. Arsenical-based cancer drugs. Cancer Treat. Rev. 33, 542-564.
  • Dong J., Su S. Y., 2008. The association between arsenic and children's intelligence: A meta-analysis. Biol. Trace Elem. Res. 129, 88-93.
  • Drewniak Ł., Skłodowska A., 2007. Rola bakterii w biogeochemicznym cyklu arsenu. Post. Mikrobiol. 46, 275-285
  • Dziubek J., 2006. Badania technologiczne nad usuwaniem związków arsenu ze ścieków przemysłowych. Ochrona Środowiska 28, 41-44.
  • Grossl P. R., Eick M. J., Grafe M., 2004. Biogeochemistry of arsenic in iron oxide systems. Supersoil 2004: Proceedings of the 3rd Australian New Zealand Soils Conference, University of Sydney, Australia, 5-9 December 2004.
  • Hughes M. F., 2002. Arsenic toxicity and potential mechanism of action. Toxicol. Lett. 133, 1-16.
  • Jędrzejczak W., 2001. Trójtlenek arsenu w leczeniu ostrej białaczki promielocytowej. Wsp. Onkol. 5, 145-146.
  • Jolliffie D. M., 1993. A history of use of arsenicals in man. J. R. Soc. Med. 86, 287-289.
  • Kabata-pendias A., Pendias H., 1993. Biogeochemia pierwiastków śladowych. PWN, Warszawa.
  • Katsoyiannis I. A., Hug S., Amman A., Zikoudi A., Hatziliontos Ch., 2007. Arsenic speciation and uranium concentrations in drinking water supply wells in Northern Greece: Correlations with redox indicative parameters and implications for groundwater treatment. Sci. Total Environ. 383, 128-140.
  • Krüger T., Holländer H. M., Boochs P. W., Billib M., Stummeyer J., Harazum B., 2007. In situ remediation of arsenic at highly contaminated site in Northern Germany. 6th International Groundwater Quality Conference held in Fremantle, Western Australia, 1-8.
  • Li D., An D., Zhou Y., Liu J., Waalkes M., P., 2006. Current status and prevention strategy for coal-arsenic poisoning in Guizhou, China. J. Health Popul. Nutr. 24, 273-276.
  • Matovu E., Enyaru J. C. K., Legros D., Schmid D., Seebeck T., Kaminsky R., 2001. Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda. Trop. Med. Int. Health 6, 407-411.
  • Mondal P., Majumder C. B., Mohanty B., 2006. Laboratory based approaches for arsenic remediation from contaminated water: Recent developments. J. Haz. Mater. B137, 464-479.
  • Mukhopadhyay R, Rosen B. P., Phung L. T., Silver S., 2002. Microbial arsenic: from geocycles to genes and enzymes. FEMS Microbiol. Lett. 26, 311-325.
  • Niedzielski P., Siepak M., Siepak J., 2000. Występowanie i zawartości arsenu, antymonu i selenu w wodach i innych elementach środowiska. Środkowo-Pomorskie Towarzystwo Naukowe Ochrony Środowiska 15, 317-341.
  • Oremland R. S., Stolz J. F., 2005. Arsenic, microbes and contaminated aquifers. Trends Microbiol. 13, 45-49.
  • Rosen B., P., 2002. Biochemistry of arsenic detoxification. FEBS Lett. 529, 86-92
  • Rosen B. P., Zijuan L., 2008. Transport pathways for arsenic and selenium: A minireview. Environ Int doi:10.1016/j.envint.2008.07.023.
  • Rossman T. G., 2003. Mechanism of arsenic carcinogenesis: an integrated approach. Mutat. Res. 533, 37-65.
  • Salnikow K., Zhitkovich A., 2008. Genetic and epigenetic mechanisms in metal carcinogenesis and cocarcinogenesis: nickel, arsenic, and chromium. Chem. Res. Toxicol. 21, 28-44.
  • Sun G., 2004. Arsenic contamination and arsenicosis in China. Toxicol. Appl. Pharmacol. 198, 268-271.
  • The World Bank Enviroment And Social Unit - South Asia Region, Water And Sanitation Program - South And East Asia, 2004. Arsenic contamination of groundwater in South and East Asia countries, Volume II technical report.
  • Tiekink E., Gielen M., 2005. Metalloterapeutic drugs and metal-based diagnostic agents the use of metals in medicine. Wiley & Sons.
  • Tseng C. H., 2007. Arsenic methylation, urinary arsenic metabolites and human diseases: current perspective. J. Environ. Sci. Health C 25, 1-22.
  • Tseng C. H., Tseng C. P., Chiou H. Y., Hsueh Y. M., Chong C. K., Chen C. J., 2002. Epidemiologic evidence of diabetogenic effect of arsenic. Tox. Lett. 133, 69-76.
  • Turpeinen R., Pantsar-kallio M, Kairesalo T., 2002 Role of microbes in controlling the speciation of arsenic and production of arsines in contaminated soils. Sci. Total Environ. 285, 133-145.
  • Vahter M., 2007. Health effects of early life exposure to arsenic. Basic Clin. Pharmacol. Toxicol. 102, 204-211.
  • Wang S. X., Wang Z. H., Cheng X. T., Li J., Sang Z. P., Zhang X. D., Han L. L., Qiao X. Y., Wu Z. M., Wang Z., 2007. Arsenic and fluoride exposure in drinking water: children's IQ and growthin shanyin county, Shanxi Province, China. Environ. Health Perspect. 115, 643-647.
  • Waxman S., Anderson K. C., 2001. History of the development of arsenic derivatives in cancer therapy. Oncologist 6, 3-10.
  • Wysocki R., Wiśniewska E., 2002 Molekularne podstawy działania arszeniku w komórkach białaczki promielocytowej. Post. Biochem. 48, 121-130.
  • Yu G., Sun D., Zheng Y., 2007. Health effects of exposure to natural arsenic in groundwater and coal in China: An Overview of Occurrence. Environ. Health Perspect. 115, 636-642.
  • Zirar S. B., Astier A., Muchow M., Gibaud S., 2008. Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice. Eur. J. Pharm. Biopharm. 70, 649-656.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.